Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.
Volume / Issue
Start / End Page
Pubmed Central ID
International Standard Serial Number (ISSN)